NASDAQ:TOI Oncology Institute (TOI) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free TOI Stock Alerts $1.18 +0.05 (+4.42%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$1.13▼$1.2250-Day Range$1.13▼$1.9752-Week Range$0.33▼$2.66Volume61,406 shsAverage Volume125,887 shsMarket Capitalization$87.69 millionP/E RatioN/ADividend YieldN/APrice Target$2.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Oncology Institute alerts: Email Address Oncology Institute MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside90.7% Upside$2.25 Price TargetShort InterestHealthy0.84% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.67Based on 4 Articles This WeekInsider TradingSelling Shares$90,550 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.36) to ($0.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.72 out of 5 starsMedical Sector628th out of 910 stocksOffices & Clinics Of Medical Doctors Industry4th out of 7 stocks 3.5 Analyst's Opinion Consensus RatingOncology Institute has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageOncology Institute has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.84% of the float of Oncology Institute has been sold short.Short Interest Ratio / Days to CoverOncology Institute has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncology Institute has recently increased by 12.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOncology Institute does not currently pay a dividend.Dividend GrowthOncology Institute does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TOI. Previous Next 0.7 News and Social Media Coverage News SentimentOncology Institute has a news sentiment score of -0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Oncology Institute this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for TOI on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Oncology Institute to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncology Institute insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $90,550.00 in company stock.Percentage Held by Insiders13.10% of the stock of Oncology Institute is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 36.86% of the stock of Oncology Institute is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Oncology Institute are expected to grow in the coming year, from ($0.36) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncology Institute is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncology Institute is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncology Institute has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Oncology Institute Stock (NASDAQ:TOI)The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.Read More TOI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TOI Stock News HeadlinesApril 23, 2024 | finance.yahoo.comThe Oncology Institute Announces First Quarter 2024 Earnings Release Date and Conference CallApril 21, 2024 | msn.comHow each zodiac signs shows they are more than just friendsApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 18, 2024 | msn.comColon cancer rates are rising in young people. If you have two symptoms you should get a colonoscopy, a GI oncologist says.April 18, 2024 | markets.businessinsider.comTopicus.com Inc. Announces Release Date for First Quarter ResultsApril 10, 2024 | msn.comDaily healthy habits to reduce cancer riskApril 8, 2024 | finance.yahoo.comJordan McInerney Appointed as Chief Development Officer of The Oncology InstituteApril 4, 2024 | globenewswire.comThe Oncology Institute and Healthly Forge Strategic Alliance to Elevate Cancer Care Access to Healthly Patients Across Southern CaliforniaApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 4, 2024 | msn.comCentre for early cancer detection is gifted £11mApril 2, 2024 | msn.comStudy finds AI empowers patients before and after seeing physicians for radiation oncology treatmentApril 2, 2024 | msn.comMan dies after 3 hospitals deny entry in DelhiApril 1, 2024 | finance.yahoo.comThe Oncology Institute, Inc. (NASDAQ:TOI) Q4 2023 Earnings Call TranscriptMarch 30, 2024 | msn.comAre we over-looking elderly loneliness?March 29, 2024 | msn.comFor unity in Covid fight, called for clanging utensils, despite ridicule: PM ModiMarch 29, 2024 | finance.yahoo.comOncology Institute Full Year 2023 Earnings: US$0.92 loss per share (vs US$0.001 profit in FY 2022)March 28, 2024 | finance.yahoo.comQ4 2023 Oncology Institute Inc Earnings CallMarch 27, 2024 | benzinga.comRecap: Oncology Institute Q4 EarningsMarch 27, 2024 | finance.yahoo.comThe Oncology Institute Inc (TOI) Reports Mixed Q4 and Full Year 2023 ResultsMarch 27, 2024 | globenewswire.comThe Oncology Institute Reports Fourth Quarter and Full Year 2023 Financial Results and Guidance for 2024March 24, 2024 | msn.comFree HPV vaccine given to 135 survivors of sexual abuseMarch 24, 2024 | msn.comPhiladelphia College of Osteopathic Medicine and The Wistar Institute Launch Joint Cancer Biology Ph.D. ProgramMarch 23, 2024 | msn.comDoctors say diagnosis of Princess Catherine’s cancer is a familiar scenarioMarch 21, 2024 | msn.comPCOM and The Wistar Institute are launching a cancer biology graduate programMarch 20, 2024 | markets.businessinsider.comPCOM, The Wistar Institute Announce Cancer Biology Graduate ProgramMarch 19, 2024 | msn.comPGIMER honoured at 5th Entrepreneur and Achiever Award 2024March 19, 2024 | msn.comNew imaging technology for diagnosing and treating bowel cancer patientsSee More Headlines Receive TOI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncology Institute and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today4/23/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Offices & clinics of medical doctors Sub-IndustryN/A Current SymbolNASDAQ:TOI CUSIPN/A CIK1799191 Webtheoncologyinstitute.com Phone562-735-3226FaxN/AEmployees800Year FoundedN/APrice Target and Rating Average Stock Price Target$2.25 High Stock Price Target$2.50 Low Stock Price Target$2.00 Potential Upside/Downside+90.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,070,000.00 Net Margins-24.56% Pretax Margin-25.63% Return on Equity-80.46% Return on Assets-28.14% Debt Debt-to-Equity Ratio1.52 Current Ratio4.12 Quick Ratio3.73 Sales & Book Value Annual Sales$324.24 million Price / Sales0.27 Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book1.53Miscellaneous Outstanding Shares74,310,000Free Float64,578,000Market Cap$87.69 million OptionableNot Optionable Beta0.68 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Richard Alan Barasch (Age 70)Executive Chairman of the Board Dr. Daniel Virnich FACHE (Age 45)M.D., MBA, Chief Executive Officer Comp: $606.08kMr. Mihir Arunkumar Shah CPA (Age 46)Chief Financial Officer & Principal Accounting Officer Comp: $393.65kMs. Hilda Agajanian M.B.A.Founder & Chief Growth OfficerDr. Richy Agajanian M.D.Founder & Chief Clinical OfficerMr. Jeremy N. Castle M.B.A. (Age 40)Chief Operations Officer Mr. Rakesh Singh M.B.A.Director of TechnologyMr. Mark Hueppelsheuser Esq.General CounselMr. Khurrum Shah J.D.M.B.A., Senior Vice President of ComplianceMs. Julie KorinkeDirector of Marketing & CommunicationsMore ExecutivesKey CompetitorsSHL TelemedicineNASDAQ:SHLTPono Capital TwoNASDAQ:PTWOClearside BiomedicalNASDAQ:CLSDAclaris TherapeuticsNASDAQ:ACRSARYA Sciences Acquisition Corp IVNASDAQ:ARYDView All CompetitorsInsiders & InstitutionsQuattro Financial Advisors LLCBought 55,960 shares on 4/18/2024Ownership: 0.075%Kent Lake Capital LLCBought 901,956 shares on 2/14/2024Ownership: 1.471%Tower Research Capital LLC TRC Bought 12,046 shares on 2/13/2024Ownership: 0.016%Cincinnati Insurance Co.Bought 699,500 shares on 2/8/2024Ownership: 0.948%Josh Arnold Investment Consultant LLCSold 21,143 shares on 2/7/2024Ownership: 2.517%View All Insider TransactionsView All Institutional Transactions TOI Stock Analysis - Frequently Asked Questions Should I buy or sell Oncology Institute stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncology Institute in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TOI shares. View TOI analyst ratings or view top-rated stocks. What is Oncology Institute's stock price target for 2024? 1 Wall Street analysts have issued 12 month price objectives for Oncology Institute's shares. Their TOI share price targets range from $2.00 to $2.50. On average, they predict the company's share price to reach $2.25 in the next twelve months. This suggests a possible upside of 90.7% from the stock's current price. View analysts price targets for TOI or view top-rated stocks among Wall Street analysts. How have TOI shares performed in 2024? Oncology Institute's stock was trading at $2.04 at the start of the year. Since then, TOI stock has decreased by 42.2% and is now trading at $1.18. View the best growth stocks for 2024 here. When is Oncology Institute's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TOI earnings forecast. How were Oncology Institute's earnings last quarter? The Oncology Institute, Inc. (NASDAQ:TOI) released its quarterly earnings data on Wednesday, March, 27th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.10. The firm earned $85.79 million during the quarter, compared to the consensus estimate of $82.04 million. Oncology Institute had a negative net margin of 24.56% and a negative trailing twelve-month return on equity of 80.46%. What guidance has Oncology Institute issued on next quarter's earnings? Oncology Institute issued an update on its FY 2024 earnings guidance on Wednesday, March, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $400.0 million-$415.0 million, compared to the consensus revenue estimate of $378.8 million. Who are Oncology Institute's major shareholders? Oncology Institute's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Quattro Financial Advisors LLC (0.08%). Insiders that own company stock include Brad Hively, Havencrest Healthcare Partners, Matthew P Miller, Mohit Kaushal, Richard A Barasch and Richy Agajanian. View institutional ownership trends. How do I buy shares of Oncology Institute? Shares of TOI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TOI) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersIs Tesla going out of business?DTI Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Oncology Institute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
